Document Detail


Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
MedLine Citation:
PMID:  15529259     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of the present study was to determine the prevalence and incidence of virological triple drug-class failure (TCF) and to summarize the clinical outcome for patients who started receiving highly active antiretroviral therapy (HAART). METHODS: The present study is an observational longitudinal study of 3496 treatment-experienced (TE) and treatment-naive (TN) patients monitored from the time they started receiving HAART (baseline) until TCF occurred (as determined on the basis of viral loads), until AIDS was newly diagnosed, or until death. RESULTS: Four hundred forty-five patients (12.7%) had TCF; 370 (16.6%) of 2230 patients were TE, and 75 (5.9%) of 1266 patients were TN. At 6 years after starting HAART, 21.4% of TE and 11.2% of TN patients had TCF (P<.0001). The prevalence of TCF at or after 2002 was 15.5% in TE patients and 4.8% in TN patients. TN patients had a 32% annual increase in the incidence of TCF (95% confidence interval [CI], 14%-54%; P<.0001); at 5 years after starting HAART, the rate was comparable for TE and TN patients (3.3 and 3.4 cases/100 person-years of follow-up [PYFU], respectively). The incidence of new cases of AIDS or death was 2.7 cases/100 PYFU in patients who did not experience TCF and 5.0 cases/100 PYFU in patients who did experience TCF, an estimated 36% increase with each category of TCF (95% CI, 19%-56%; P<.0001). CONCLUSION: The prevalence of TCF was low after patients started receiving HAART, particularly among TN patients. Despite the influx of patients who had started receiving HAART more recently, the prevalence of TCF increased over calendar time. Patients with TCF had a higher incidence of newly diagnosed AIDS or death. Treatment of patients with TCF deserves further investigation.
Authors:
A Mocroft; B Ledergerber; J P Viard; S Staszewski; M Murphy; A Chiesi; A Horban; A-B E Hansen; A N Phillips; J D Lundgren;
Related Documents :
9540779 - Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin gen...
20188859 - Identification of a high-risk population for esophageal injury during radiofrequency ca...
8308339 - Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and...
12948919 - Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 ...
12269519 - Cardioversion of atrial fibrillation with ibutilide: when is it most effective?
20421959 - Serological predictors for the recurrence of atrial fibrillation after electrical cardi...
9152619 - Incidence of hyperprolactinemia in patients with hashimoto's thyroiditis.
18355919 - Secondary myelodysplastic syndrome in a patient with philadelphia-positive acute lympho...
10555039 - Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of pa...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2004-10-28
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  190     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-11-05     Completed Date:  2004-12-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1947-56     Citation Subset:  AIM; IM    
Affiliation:
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, London, United Kingdom. a.mocroft@pcps.ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / epidemiology,  mortality
Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Cohort Studies
Confidence Intervals
Europe / epidemiology
Female
Follow-Up Studies
HIV Infections / drug therapy*,  epidemiology
HIV-1*
Humans
Incidence
Male
Prevalence
Time Factors
Treatment Failure
Viral Load
Chemical
Reg. No./Substance:
0/Anti-HIV Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.
Next Document:  Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phas...